An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals
المؤلفون المشاركون
Van Binst, A.
Neyns, Bart
De Witte, O.
Michotte, Alex
Luce, S.
Huylebrouck, M.
Duerinck, Johnny
De Greve, J.
Salmon, I.
Lv, S.
D'Haens, J.
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-8، 8ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-03-13
دولة النشر
مصر
عدد الصفحات
8
التخصصات الرئيسية
الملخص EN
Background.
Bevacizumab (BEV), a humanized immunoglobulin G1 monoclonal antibody that inhibits VEGF has demonstrated activity against recurrent high-grade gliomas (HGG) in phase II clinical trials.
Patients and Methods.
Data were collected from patients with recurrent HGG who initiated treatment with BEV outside a clinical trial protocol at two Belgian university hospitals.
Results.
19 patients (11 M/8 F) were administered a total of 138 cycles of BEV (median 4, range 1–31).
Tumor response assessment by MRI was available for 15 patients; 2 complete responses and 3 partial responses for an objective response rate of 26% for the intent to treat population were observed on gadolinium-enhanced T1-weighted images; significant regressions on T2/FLAIR were documented in 10 out of 15 patients (67%).
A reduced uptake on PET was documented in 3 out of 4 evaluable patients.
The six-month progression-free survival was 21% (95% CI 2.7–39.5).
Two patients had an ongoing tumor response and remained free from progression after 12 months of BEV treatment.
Conclusions.
The activity and tolerability of BEV were comparable to results from previous prospective phase II trials.
Reduced uptake on PET suggests a metabolic response in addition to an antiangiogenic effect in some cases with favorable clinical outcome.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Huylebrouck, M.& Lv, S.& Duerinck, Johnny& Van Binst, A.& Salmon, I.& De Greve, J.…[et al.]. 2012. An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals. Journal of Oncology،Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-499104
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Huylebrouck, M.…[et al.]. An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals. Journal of Oncology No. 2012 (2012), pp.1-8.
https://search.emarefa.net/detail/BIM-499104
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Huylebrouck, M.& Lv, S.& Duerinck, Johnny& Van Binst, A.& Salmon, I.& De Greve, J.…[et al.]. An Observational Study of the First Experience with Bevacizumab for the Treatment of Patients with Recurrent High-Grade Glioma in Two Belgian University Hospitals. Journal of Oncology. 2012. Vol. 2012, no. 2012, pp.1-8.
https://search.emarefa.net/detail/BIM-499104
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-499104
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر